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Abstract
Viral hepatitis is one of the major health problems worldwide, particularly in South East Asian countries including
Pakistan where hepatitis C virus (HCV) and hepatitis B virus (HBV) infections are highly endemic. Hepatitis delta
virus (HDV) is also not uncommon world-wide. HCV, HBV, and HDV share parallel routes of transmission due to
which dual or triple viral infection can occur in a proportion of patients at the same time. HBV and HCV are
important factors in the development of liver cirrhosis (LC) and hepatocellular carcinoma (HCC). In addition to LC
and HCC, chronic HDV infection also plays an important role in liver damage with oncogenic potential.
The current article reviews the available literature about the epidemiology, pathogenesis, transmission, symptoms,
diagnosis, replication, disease outcome, treatment and preventive measures of triple hepatitis infection by using
key words; epidemiology of triple infection, risk factors, awareness status, treatment and replication cycle in
PubMed, PakMediNet, Directory of Open Access Journals (DOAJ) and Google Scholar. Total data from 74 different
studies published from 1983 to 2010 on triple hepatitis infections were reviewed and included in this study. The
present article briefly describes triple infection with HCV, HBV and HDV.
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Introduction
Hepatitis is a Latin word which means inflammation of
liver. At the present time viral hepatitis is a major health
problem worldwide, particularly in Asian countries [1].
Hepatitis is caused by different hepatic viruses and it leads
to liver related morbidity [2-4]. Mostly hepatic infection is
caused by single hepatic virus but sometime infection with
multiple viruses may occur and it leads to different man-
agement problems. These different problems include
higher incidence of morbidity and mortality [5].
As hepatitis C virus (HCV), hepatitis B virus (HBV) and
hepatitis D virus (HDV) are transmitted via similar routes
that is through blood or blood products so as a result,
dual infection and even triple infection can occur in some
patients [1,6-10] at the same time. A condition in which
all three viruses (Hepatitis B, C and D) occur together in
the same patient is called Triple infection [1].
Viral hepatitis is one of the major health issues these
days [11,12]. HBV is a partially double stranded, envel-
oped DNA virus that belongs to the Hepadnaviridae
family and Orthohepadnavirus genus. Its size ranges
from 40 to 42 nm, replicates in the liver and causes
hepatic abnormalities [13,14]. It damages liver through
immune mediated mechanisms [15,16]. HBV is the 9
th
leading cause of death worldwide. There are about 400
million people worldwide who are HCV carriers [17]. It
causes cirrhosis, liver failure and hepatocellular carci-
noma (HCC) [18]. Annually one million people die due
to HBV [19,20]. It has worldwide distribution and is
also well documented in Pakistan [21,22].
HCV is a single stranded RNA, enveloped virus that
belongs to Flaviviridae family [23]. More than 170 million
people are infected with HCV in the world [24]. Like
HBV, it replicates in the liver and causes liver abnormal-
ities. Like HBV, it also leads to many serious complica-
tions including cirrhosis, liver injury and hepatocellular
carcinoma (HCC) [25,26]. These two (HBV and HCV) are
the main causes of chronic hepatitis [2,4]. HBV and HCV
infection are common in those areas where these two
viruses are endemic [27-31].
Hepatitis D virus (HDV) or delta virus is a defective
virus. It requires the help of another virus that is hepati-
tis B virus for its multiplication. It always occur with
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tion. It is very rare but most severe form of the viral
hepatitis [32]. This virus cannot replicate or multiply in
t h ea b s e n c eo fH B V[ 9 ] .S ow ec a ns a yt h a tH D Vi st h e
result of HBV [33,34]. Worldwide 15 million people
positive for hepatitis B are also infected with hepatitis D
[35]. Like HBV and HCV, it also plays a significant role
in liver abnormalities. It also has oncogenic abnormal-
ities [36,37].
Literature Search
Epidemiology of triple viral infection
Cases of triple viral infections and multiple viral infections
had been reported from different regions of the world
[5,10,38,39]. Mongolia is a country which is highly ende-
mic for triple hepatitis viruses (with HBV, HCV, and
HDV). Consequently many cases of triple infection are
reported from here. It is also been reported that in Mon-
golia there is high prevalence of HBV, HCV and HDV
[5,38,40-42]. There are also other regions of the world
from where triple viral hepatitis infections had been
reported including India and China [43,44]. Taiwan is
another country which was previously reported as HBV
and HCV endemic area but recent studies showed that
now it is also endemic for HDV. Many cases of triple
infection of hepatitis viruses are also reported from this
region. Among the triple hepatitis patients in Taiwan, the
prevalence of HBV is 12.6%, HCV is 41.6% and that of
HDV is 15.3% [1]. Up to now, there is no report on triple
infection caused by hepatitis viruses from Pakistani popu-
lation [38].
Pathogenesis
There are many controversies about the role of triple
hepatic infection in the pathogenesis of liver disease. It
has been reported that triple viral infection does not
cause the development of HCC but only one virus that
dominate other two viruses in triple viral infection causes
this condition of HCC [43].
Transmission routes
HBV, HCV and HDV viruses are not only biologically
different but their life cycles and modes of gene expres-
sion are also totally different from each other. Despite of
all these differences, they share same routes of transmis-
sion [45]. These three viruses (HBV, HCV, and HDV) are
the major causes of chronic liver disease. All three viruses
(HBV, HCV, and HDV) are transmitted due to direct or
indirect exposure to infected blood or body fluids that
contain infected blood. Common routes for transmission
of these viruses are infected blood transfusion, contami-
nated syringes, injecting, tattoo and skin piercing with
infected instruments, infected household contacts,
through infected mother to her baby, by sexual contact
with infected person, and via sharing of needles contami-
nated by infected drug users etc [46]. It is not unusual to
find a patient who is co-infected with HBV and HCV or
HBV and HDV or with all three viruses (HBV, HCV, and
HDV) [1,5-8,47,48].
Symptoms
Viral hepatitis is of major concern as it leads to morbidity
and mortality. Whatever its cause is, all types of viral
hepatitis affect liver cells. As a result, many signs and
symptoms of various types of hepatitis are almost similar
and these are not specific to the viral agent that causes
them. Most common symptoms are yellowed eyes or skin
(jaundice), fever, fatigue, loss of appetite, joint pain,
abdominal pain, diarrhea, nausea, vomiting, dark urine
and flu-like symptoms. Some patients may experience
few or no symptoms [49-52].
Diagnosis
Diagnosis of hepatic viral infection is carried out by study-
ing biochemical, virological and histological parameters.
Liver function tests (LFT) and serologic assays are also
used for detection of antigens and antibodies. As all hepa-
titis viral infections have same sign and symptoms so it is
very difficult to diagnose triple viral infection. A liver func-
tion test is available but the pattern of abnormality for
acute infection is similar for all types of viral hepatitis.
Individually each infection (HBV, HCV and HDV) is con-
firmed by the presence of the serum surface antigen, hepa-
titis B, C and D envelope antigen and specific antibodies to
the hepatitis B, C and D core. Moreover polymerase chain
reaction (PCR) and enzyme linked immunosorbant assay
(ELISA) are also used for confirmation [53]. Diagnosis of
HCV infection is done by detecting anti-HCV antibody by
E L I S Am e t h o do rH C VR N Ab yP C Rm e t h o di nt h e
serum. HDV is diagnosed by the presence of anti-HDV
antibody in the serum using specific ELISA assay. Diagno-
sis of multiple hepatitis viral infections using one assay is
not possible to date. It may be due to low level of aware-
ness among physicians and availability of simple diagnostic
tests. But recently scientists used a single integrated pro-
tein micro-array for diagnosing multiple viral infections. It
can determine two viral antigens (HBsAg, HBeAg) and
seven viral antibodies (HBsAb, HBcAb, HBeAb, HCVAb,
HDVAb, HEVAb, HGVAb) of human hepatitis viruses in
human sera just within 20 minutes [38,54]. However this
is very expensive and available in developed countries
only.
Replication status of viruses in triple infection
Although the replication pathway of HBV, HCV and
HDV are different but one interesting virological aspect
in case of triple infection is that up to what extent each
virus affects the replication pathway of other virus and
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disease. The reciprocal influence of HBV, HCV and
HDV is still not clear [47,55]. In triple infection with
HBV, HCV and HDV, there is interference between the
viruses. In such situation one virus might suppresses the
effect of others. As some studies have shown that HCV
suppresses the effect of HBV and HDV and in some
cases it causes sero-clearance of HBV antigens. Similarly
there are studies which reported that HBV and HDV
suppress HCV effect [48].
Several studies have shown that HDV act as a dominant
virus in triple infection and it inhibits the replication of
both HBV and HCV [47,48,56-59]. Some studies have also
shown that HCV is cleared when patient is super-infected
with HBV and HDV [60]. The reason for this could be the
inhibition of markers required for their replication [47,58].
Actually large delta antigen of HDV inhibits the host
DNA dependent RNA polymerase II which is involved in
HBV replication [58,61]. However, some studies reported
that HCV act as a dominant virus in triple infection. A
study conducted on triple infection of HBV, HCV and
HDV by Liaw and colleagues showed that newcomer virus
suppress existent viruses [62]. Another study in Australia
showed that in patients infected with HBV, HCV and
HDV, replication of HBV is suppressed [63]. A study done
by Mathurin showed that in Western countries dominant
virus is HDV and there is no replication of HCV and HBV
in patients with triple infection. Such discrepancies
between the studies can be explained as the time of infec-
tion and host immune status are different in different
parts of the world as a result of which different viruses are
dominant in triple infection in different parts of the world
[47].
Disease outcome
As in triple infection all the three viruses are present so
scientists are of the view that there are more complica-
tions in the early appearance of this disease [64]. A study
conducted by Liaw et al on the disease outcome of triple
infection with HBV, HCV and HDV reported that this
disease is more severe in the acute super-infection stage
[62]. Other studies also suggested that infection with
HBV, HCV and HDV increases the risk of fulminant
hepatitis which is severe impairment of hepatic functions
or severe necrosis of hepatocytes [65,66]. Patients with
triple infection of HBV, HCV and HDV suffer from more
severe liver lesions. They show a high tendency for cir-
rhosis. They also show increased risk for progression to
HCC [63,67-69].
Treatment
Virological response in case of triple infection varies
widely and show many different profiles. As a result of
this, level of viruses varies during the therapy and
follow-up period. For a proper treatment of triple infec-
tion, patient should be followed up yearly and the viral
load should be determined which tells us which one
virus is gone to be dominant and then we can treat it
accordingly [70]. Patients with triple infection involving
HBV, HCV and HDV show severe and progressive liver
disease. Many studies have shown that when patients
with triple infection are treated with interferon therapy,
they show resistance to interferon therapy whereas
patients having a single viral infection respond to his
therapy [48]. Weltman et al., also reported that when
seven patients having triple infection were treated with
interferon-alpha, six show no response and there is only
one patient who normalized serum alanine aminotrans-
ferase (ALT) during treatment. So they provide a proof
that triple infection show less response to interferon
therapy [63].
When patients with triple infection involving HBV,
HCV and HDV are treated with lamivudine alone and
lamivudine in combination with interferon, they have
not shown positive results [71,72]. Another option for
patients with triple infection involving HBV, HCV and
HDV is liver transplantation. Risk of recurrence of
HBV and HCV is decreased in transplanted liver which
otherwise may occur due to viral interference phenom-
enon [73]. Treatment options for triple infection invol-
ving HBV, HCV and HDV are very limited. There is
no optimal treatment for this up to now [73]. For
selecting most appropriate antiviral treatment of triple
infection, patient should be monitored carefully and
virological assessment should be carried out to deter-
mine dominant virus.
Preventive measures
There are a lot of preventive measures which should be
carried out in order to avoid development of triple
infection. Some of these are [74]:
1. Screening of donated blood and plasma
2. Routine immunization for infants and high-risk
individuals
3. Practicing safe sex
4. Cleaning up blood spills promptly with bleach
5. Avoiding sharing razors, syringes, tooth brushes,
nail clippers, or needles, when getting a manicure, a
tattoo, or having any body part pierced [74].
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